(Q50937869)

25 March 2018

title

Meformin, plasma glucose and free fatty acids in type II diabetic out-patients: results of a clinical study. (English)

1 reference

25 March 2018

author name string

Gregorio F

1

1 reference

25 March 2018

Ambrosi F

2

1 reference

25 March 2018

Manfrini S

3

1 reference

25 March 2018

Santucci A

4

1 reference

25 March 2018

Filipponi P

5

1 reference

25 March 2018

publication date

1 July 1997

1 reference

25 March 2018

Diabetes Research and Clinical Practice

published in

1 reference

25 March 2018

volume

37

1 reference

25 March 2018

issue

1

1 reference

25 March 2018

page(s)

21-33

1 reference

25 March 2018

Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900047-8

7 January 2021

Metabolic origin of insulin resistance in obesity with and without type 2 (non-insulin-dependent) diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900047-8

7 January 2021

Mechanisms modifying glucose oxidation in diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900047-8

7 January 2021

Fatty acids, hyperinsulinemia, and insulin resistance: which comes first?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900047-8

7 January 2021

Impaired fatty acid metabolism in familial combined hyperlipidemia. A mechanism associating hepatic apolipoprotein B overproduction and insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900047-8

7 January 2021

Metabolic implications of body fat distribution

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900047-8

7 January 2021

The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900047-8

7 January 2021

Insulin resistance and body fat distribution.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900047-8

7 January 2021

Fatty acids and insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900047-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900047-8

1 reference

7 January 2021

Different effects of insulin and oral antidiabetic agents on glucose and energy metabolism in type 2 (non-insulin-dependent) diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900047-8

7 January 2021

Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900047-8

7 January 2021

Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900047-8

7 January 2021

Combined metformin-sulfonylurea treatment of patients with noninsulin-dependent diabetes in fair to poor glycemic control

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900047-8

7 January 2021

Effect of metformin on postprandial lipemia in patients with fairly to poorly controlled NIDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900047-8

7 January 2021

The effect of metformin on adipose tissue metabolism and peripheral blood flow in subjects with NIDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900047-8

7 January 2021

Metformin and free fatty acid metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900047-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900047-8

1 reference

7 January 2021

The impact of metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase activity in overweight type II diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900047-8

7 January 2021

Metabolic effects of metformin in non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900047-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900047-8

1 reference

7 January 2021

The Influence of Regional Adiposity on Atherogenic Risk Factors in Men and Women with Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900047-8

7 January 2021

Obesity: new insight into the anthropometric classification of fat distribution shown by computed tomography

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900047-8

7 January 2021

Statistics in practice. Comparing the means of several groups.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900047-8

7 January 2021

Prevalence of diabetes and impaired glucose tolerance in elderly subjects and their association with obesity and family history of diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900047-8

7 January 2021

Increased rate of gluconeogenesis in type II diabetes mellitus. A 13C nuclear magnetic resonance study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900047-8

7 January 2021

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900047-8

7 January 2021

Different aetiologies of type 2 (non-insulin-dependent) diabetes mellitus in obese and non-obese subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900047-8

7 January 2021

New Pharmacological Approaches to Therapy of NIDDM

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900047-8

7 January 2021

Mechanism for the stimulation of gluconeogenesis by fatty acids in perfused rat liver

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900047-8

7 January 2021

Demonstration of a critical role for free fatty acids in mediating counterregulatory stimulation of gluconeogenesis and suppression of glucose utilization in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900047-8

7 January 2021

Decreased hepatic insulin extraction in upper body obesity: relationship to unbound androgens and sex hormone binding globulin

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900047-8

7 January 2021

Opposite effects of short- and long-term fatty acid infusion on insulin secretion in healthy subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900047-8

7 January 2021

Long-term exposure of rat pancreatic islets to fatty acids inhibits glucose-induced insulin secretion and biosynthesis through a glucose fatty acid cycle

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900047-8

7 January 2021

Non-esterified fatty acids regulate lipid and glucose oxidation and glycogen synthesis in healthy man.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900047-8

7 January 2021

Glucose-fatty acid cycle operates in humans at the levels of both whole body and skeletal muscle during low and high physiological plasma insulin concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900047-8

7 January 2021

Insulin action on the adenyl cyclase system: Antagonism to activation by lipolytic hormones

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900047-8

7 January 2021

Hormone-sensitive lipase--a multipurpose enzyme in lipid metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900047-8

7 January 2021

Interactions of insulin and adrenaline with glycerol phosphate acylation processes in fat-cells from rat

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900047-8

7 January 2021

Metformin's effects on glucose and lipid metabolism in patients with secondary failure to sulfonylureas.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900047-8

7 January 2021

Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900047-8

7 January 2021

Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900047-8

7 January 2021

Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900047-8

7 January 2021

Cholesterol Lowering Effect of Metformin in Combined Hyperlipidemia: Placebo Controlled Double Blind Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900047-8

7 January 2021

Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900047-8

7 January 2021

10.1016/S0168-8227(97)00047-8

Identifiers

DOI

1 reference

25 March 2018

1 reference

25 March 2018